Core Insights - Rigel Pharmaceuticals announced the publication of five-year data from a Phase 2 trial of REZLIDHIA (olutasidenib) for treating relapsed or refractory mutant isocitrate dehydrogenase-1 acute myeloid leukemia (mIDH1 AML) [1][2] Efficacy and Safety Data - The five-year follow-up analysis supports the durable responses and manageable safety profile of olutasidenib, including efficacy in patients previously treated with venetoclax [2][5] - Among 147 efficacy evaluable patients, the complete remission (CR) or CR with partial hematologic recovery (CRh) rate was 35%, with a median duration of 25.3 months [5] - The overall response rate (ORR) was 48%, with a median duration of 15.5 months, and median overall survival (OS) was 11.5 months [5] - Transfusion independence was achieved in 39% of patients dependent on red blood cells and 41% of those dependent on platelets at baseline [5] Patient Response Insights - 66% of patients who achieved an overall response did so within 2 months, while 10% required at least 4.6 months of therapy [5] - Patients with one to two prior regimens had a higher CR/CRh rate of 41% and a median OS of 13 months compared to those with three prior regimens [5] - In patients R/R to prior venetoclax, 33% achieved a CR/CRh, with a median OS of 16.2 months [5] Ongoing Research and Collaborations - Rigel is evaluating olutasidenib in other disease areas and has strategic collaborations with The University of Texas MD Anderson Cancer Center [4][12] - A fifth study under the strategic alliance with MD Anderson has opened for enrollment, focusing on olutasidenib in combination with co-targeted therapies [12] Industry Context - Acute myeloid leukemia (AML) is a rapidly progressing cancer affecting myeloid cells, with an estimated 22,010 new cases in the U.S. in 2025 [6] - Relapsed AML affects about half of all patients post-treatment, while refractory AML occurs in 10-40% of newly diagnosed patients [7]

Core Insights - Rigel Pharmaceuticals, Inc. is a biotechnology company focused on hematologic disorders and cancer, and it will present an overview at the Jefferies Global Healthcare Conference on November 18, 2025 [1][3]. Company Overview - Rigel Pharmaceuticals, Inc. is dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer [3]. - The company was founded in 1996 and is based in South San Francisco, California [3]. Event Details - The presentation by Raul Rodriguez, the company's president and CEO, will take place at 10:00 a.m. GMT (5:00 a.m. ET) [1]. - Investors can access the live webcast or archived recording through the Investor Relations section of the company's website [2].

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Core Viewpoint - Rigel Pharmaceuticals (RIGL) is positioned as a strong investment opportunity due to its improving earnings outlook and analysts' increasing earnings estimates [1][2]. Earnings Estimate Revisions - Analysts' optimism regarding Rigel's earnings prospects is leading to upward revisions in estimates, which historically correlate with stock price movements [2]. - The current-quarter earnings estimate is $0.94 per share, reflecting a +17.5% change from the previous year, with a 31.69% increase in the Zacks Consensus Estimate over the last 30 days [6]. - For the full year, the earnings estimate stands at $5.66 per share, indicating a significant +471.7% change from the year-ago figure, with an 11.09% increase in the consensus estimate during the same timeframe [7][8]. Zacks Rank and Performance - Rigel currently holds a Zacks Rank 1 (Strong Buy), supported by strong agreement among analysts in revising earnings estimates upward [9]. - The Zacks Rank system has a proven track record, with Zacks 1 Ranked stocks averaging a +25% annual return since 2008 [3]. - Stocks with Zacks Rank 1 and 2 are shown to significantly outperform the S&P 500 [9]. Investment Outlook - Rigel's stock has increased by 31.6% over the past four weeks due to favorable estimate revisions, suggesting potential for further upside [10].

Core Viewpoint - Rigel Pharmaceuticals (RIGL) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on an upward trend in earnings estimates, which significantly influences stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are closely correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [3][5]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional investors to buy or sell, thus affecting stock prices [3]. Rigel's Earnings Outlook - Rigel is projected to earn $5.66 per share for the fiscal year ending December 2025, with no year-over-year change expected. However, the Zacks Consensus Estimate for the company has increased by 32.8% over the past three months, indicating a positive trend in earnings outlook [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988, showcasing the effectiveness of this rating system [6][8]. - Rigel's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term due to superior earnings estimate revisions [9].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - SMX (Security Matters) Public Limited Company (SMX) increased by 52% to $2.24 [3] - Entravision Communications Corporation (EVC) rose by 33% to $2.66 [3] - Babcock & Wilcox Enterprises, Inc. (BW) saw a 28% increase to $4.79 [3] - NeuroPace, Inc. (NPCE) gained 24% reaching $11.71 [3] - Kennedy-Wilson Holdings, Inc. (KW) also increased by 24% to $9.30 [3] - Rigel Pharmaceuticals, Inc. (RIGL) rose by 22% to $34.72 [3] - Digital Turbine, Inc. (APPS) increased by 21% to $7.20 [3] - Lumentum Holdings Inc. (LITE) saw a 15% increase to $218.06 [3] - AsiaStrategy (SORA) rose by 14% to $3.63 [3] - Marine Petroleum Trust (MARPS) increased by 7% to $5.05 [3] Premarket Losers - Biohaven Ltd. (BHVN) decreased by 42% to $7.96 [4] - Trex Company, Inc. (TREX) fell by 34% to $30.65 [4] - Soleno Therapeutics, Inc. (SLNO) saw a 23% decline to $49.00 [4] - Axon Enterprise, Inc. (AXON) decreased by 19% to $572.00 [4] - Clover Health Investments, Corp. (CLOV) fell by 19% to $2.82 [4] - Pinterest, Inc. (PINS) decreased by 18% to $26.91 [4] - SSR Mining Inc. (SSRM) saw a 17% decline to $17.91 [4] - Upstart Holdings, Inc. (UPST) decreased by 16% to $38.81 [4] - WF International Limited (WXM) fell by 12% to $2.25 [4] - Corsair Gaming, Inc. (CRSR) decreased by 11% to $6.66 [4]

Core Insights - Teradata Corp reported better-than-expected third-quarter financial results, with earnings of 72 cents per share, surpassing the analyst consensus estimate of 54 cents per share [2] - The company also reported quarterly sales of $416 million, exceeding the analyst consensus estimate of $406.228 million [2] - Following the positive results, Teradata shares rose 14.6% to $23.73 in pre-market trading [2] - Additionally, Teradata raised its FY25 EPS guidance above estimates and issued fourth-quarter EPS guidance above estimates [1] Financial Performance - Teradata's quarterly earnings were 72 cents per share, beating the expected 54 cents per share [2] - Quarterly sales reached $416 million, surpassing the forecast of $406.228 million [2] Market Reaction - Teradata shares experienced a significant increase of 14.6%, reaching $23.73 in pre-market trading following the earnings report [2]

Core Insights - Rigel Pharmaceuticals (RIGL) reported quarterly earnings of $1.46 per share, exceeding the Zacks Consensus Estimate of $0.93 per share, and showing an increase from $0.7 per share a year ago, resulting in an earnings surprise of +56.99% [1] - The company achieved revenues of $69.46 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 12.80% and up from $55.31 million year-over-year [2] - Rigel's stock has increased by approximately 82.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The future performance of Rigel's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook, including current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.87 on revenues of $64.23 million, and for the current fiscal year, it is $5.49 on revenues of $280.85 million [7] Industry Context - The Medical - Drugs industry, to which Rigel belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Rigel's stock may also be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

Financial Data and Key Metrics Changes - The company reported total revenue of $69.5 million for Q3 2025, including record net product sales of $64.1 million, a 65% year-over-year increase [4][27] - Net income for the third quarter was $27.9 million, compared to $12.4 million for the same period in 2024 [29] - Cash balance increased to $137.1 million, up from $77.3 million at the end of 2024 [29] Business Line Data and Key Metrics Changes - TAVALISSE generated $44.7 million in net product sales, a 70% increase year-over-year [11][27] - GAVRETO achieved $11.1 million in net product sales, reflecting a 56% increase compared to Q3 2024 [12][27] - REZLIDHIA reported $8.3 million in net product sales, a 50% increase year-over-year [12][27] Market Data and Key Metrics Changes - The company has expanded access to TAVALISSE in Japan, Europe, Canada, Israel, and South Korea, with ongoing regulatory approvals in new markets [13] - The commercial portfolio has shown strong year-over-year growth, with net product sales exceeding $200 million on a trailing 12-month basis [11] Company Strategy and Development Direction - The strategic objectives focus on growing the hematology and oncology business through commercial performance and pipeline expansion [4] - The company is pursuing additional in-licensing deals or asset acquisitions to achieve significant growth [7] - The 2025 revenue guidance has been raised to $285-$290 million, reflecting anticipated growth of 55%-59% compared to 2024 [9][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve significant long-term growth through strong commercial execution and financial discipline [9][32] - The company aims to continue driving sales of commercial products while funding key development programs in its internal pipeline [31][32] Other Important Information - The company is advancing its development pipeline, including the ongoing phase 1b study of R289 and collaborations for olutasidenib in various cancer studies [5][16] - The company has received fast-track designation and orphan drug designation from the FDA for R289, indicating a promising regulatory pathway [19] Q&A Session Summary Question: Competitive positioning of R289 in lower-risk MDS versus Rytelo - Management indicated it is too early to speculate on competitive positioning and plans for a registrational study [34] Question: Data needed for potential priority review of R289 - Management noted that the fast-track designation opens potential for priority review, but further data from the dose expansion study is needed [38] Question: Expectations for updated data at ASH for R289 - Management confirmed that updated data will include 16 weeks of follow-up on all patients, providing a robust data set for presentation [40]

Q3 2025 Financial Results Presentation November 4, 2025 1 Forward Looking Statements Raul Rodriguez President & Chief Executive Officer Ray Furey, J.D. Executive Vice President, General Counsel & Corporate Secretary This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") relating to, among other things, continued development and expansion of our business, projected financial performance including sales and revenue growth, con ...